Rigel Pharmaceuticals, Inc, a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Phase III clinical study for autoimmune hemolytic anemia.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone650-624-1100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$44.51 million
Profitability
Miscellaneous
Employees158
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Rigel Pharmaceuticals (NASDAQ:RIGL) Frequently Asked Questions
What is Rigel Pharmaceuticals' stock symbol?
Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."
How were Rigel Pharmaceuticals' earnings last quarter?
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) issued its quarterly earnings data on Tuesday, August, 6th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.14) by $0.02. The biotechnology company earned $10.41 million during the quarter, compared to the consensus estimate of $9.25 million. Rigel Pharmaceuticals had a negative return on equity of 60.72% and a negative net margin of 89.34%. During the same period last year, the company earned ($0.16) earnings per share. View Rigel Pharmaceuticals' Earnings History.
When is Rigel Pharmaceuticals' next earnings date?
What price target have analysts set for RIGL?
3 brokerages have issued 1 year price targets for Rigel Pharmaceuticals' stock. Their predictions range from $7.00 to $8.00. On average, they anticipate Rigel Pharmaceuticals' share price to reach $7.33 in the next year. This suggests a possible upside of 341.8% from the stock's current price. View Analyst Price Targets for Rigel Pharmaceuticals.
What is the consensus analysts' recommendation for Rigel Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rigel Pharmaceuticals.
What are Wall Street analysts saying about Rigel Pharmaceuticals stock?
Here are some recent quotes from research analysts about Rigel Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer. " (8/10/2019)
- 2. Cantor Fitzgerald analysts commented, ": We reiterate our OW rating and $7 PT on Rigel following results from the period ended 3/31/2019. During the quarter, Rigel reported sales of $8.1 million for TAVALISSE for the treatment of immune thrombocytopenia (ITP), which was a slight beat vs. our $7.7 million estimate. Our near-term focus for Rigel will remain on quarterly U.S. sales for TAVALISSE. Additionally, we await an EU approval decision by year-end 2019, which could expand the revenue opportunity for Rigel and provide upfront capital of nearly $40 million from Grifols (GRFS – NC)." (5/7/2019)
- 3. HC Wainwright analysts commented, "Valuation and impediments to achieving price target. We reiterate our Buy rating though are increasing our price target to $8 from $7.50. The primary drivers to our price target change include: (1) adjustment to base year; and (2) adjustment to fully diluted share count. Our valuation is currently driven wholly by fostamatinib (Tavalisse) with 77% contribution from our U.S. and E.U. projections for cIPT and 23% contribution from our U.S. and E.U. projections for AIHA." (1/23/2019)
Has Rigel Pharmaceuticals been receiving favorable news coverage?
Media stories about RIGL stock have trended somewhat positive on Sunday, InfoTrie reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Rigel Pharmaceuticals earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Rigel Pharmaceuticals.
Are investors shorting Rigel Pharmaceuticals?
Rigel Pharmaceuticals saw a drop in short interest during the month of September. As of September 30th, there was short interest totalling 11,630,000 shares, a drop of 9.2% from the August 30th total of 12,810,000 shares. Based on an average daily volume of 1,250,000 shares, the days-to-cover ratio is presently 9.3 days. Approximately 7.1% of the shares of the stock are sold short. View Rigel Pharmaceuticals' Current Options Chain.
Who are some of Rigel Pharmaceuticals' key competitors?
Some companies that are related to Rigel Pharmaceuticals include Innoviva (INVA), Zymeworks (ZYME), ArQule (ARQL), Theravance Biopharma (TBPH), Esperion Therapeutics (ESPR), Gossamer Bio (GOSS), Dicerna Pharmaceuticals (DRNA), AnaptysBio (ANAB), TherapeuticsMD (TXMD), Amphastar Pharmaceuticals (AMPH), Epizyme (EPZM), Odonate Therapeutics (ODT), Athenex (ATNX), Y-mAbs Therapeutics (YMAB) and Amneal Pharmaceuticals (AMRX).
What other stocks do shareholders of Rigel Pharmaceuticals own?
Who are Rigel Pharmaceuticals' key executives?
Rigel Pharmaceuticals' management team includes the folowing people:
- Mr. Raul R. Rodriguez, Pres, CEO & Director (Age 58)
- Ms. Dolly A. Vance, Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. (Age 54)
- Dr. Anne-Marie S. Duliege, Exec. VP & Chief Medical Officer (Age 60)
- Mr. Eldon C. Mayer III, M.B.A., Exec. VP & Chief Commercial Officer (Age 58)
- Dr. Thomas A. Raffin, Co-Founder (Age 72)
How do I buy shares of Rigel Pharmaceuticals?
Shares of RIGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Rigel Pharmaceuticals' stock price today?
One share of RIGL stock can currently be purchased for approximately $1.66.
How big of a company is Rigel Pharmaceuticals?
Rigel Pharmaceuticals has a market capitalization of $278.23 million and generates $44.51 million in revenue each year. The biotechnology company earns $-70,480,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. Rigel Pharmaceuticals employs 158 workers across the globe.View Additional Information About Rigel Pharmaceuticals.
What is Rigel Pharmaceuticals' official website?
How can I contact Rigel Pharmaceuticals?
Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-624-1100 or via email at [email protected]
MarketBeat Community Rating for Rigel Pharmaceuticals (NASDAQ RIGL)
MarketBeat's community ratings are surveys of what our community members think about Rigel Pharmaceuticals and other stocks. Vote "Outperform" if you believe RIGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RIGL will underperform the S&P 500 over the long term. You may vote once every thirty days.
